Challenges in the treatment of anxiety disorders: beyond guidelines

References

• Kessler RC, McGonagle KA, Zhoa S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Collins KA, Westra HA, Dozois DJA, Burns DD. Gaps in accessing treatment for anxiety and depression: Challenges for the delivery of care. Clin Psychol Rev 2004; 24: 583–616
   PubMed Web of Science ®Google Scholar
• Devane CL, Chiao E, Franklin M, Kruep EJ. Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression. Am J Manage Care 2005; 12(Suppl)S344–53
   Google Scholar
• Ohayon MM, Shapiro CM, Kennedy SH. Differentiating DSM-IV anxiety and depressive disorders in the general population: comorbidity and treatment consequences. Can J Psychiatry 2000; 45(2)166–72
   Google Scholar
• Davidson JRT, Hughes DL, George LK, Blazer DG. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med 1993; 23: 709–18
   PubMed Web of Science ®Google Scholar
• Blumenthal R, Endicott J. Barriers to seeking treatment for major depression. Depress Anxiety 1996–97; 4(6)273–8
   Google Scholar
• Mojtabai R, Olfson M, Mechanic D. Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry 2002; 59(1)77–84
   PubMed Web of Science ®Google Scholar
• Kasper S. Anxiety disorders: under-diagnosed and insufficiently treated. Int J Psych Clin Pract 2006; 10(Suppl 1)3–9
   Google Scholar
• Sartorius N, Ustun TB, Lecrubier Y, Wittchen HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl 1996; 30: 38–43
   Google Scholar
• Wang PS, Berglund P, Kessler RC. Recent care of common mental disorders in the United States: prevalence and conformance with evidence-based recommendations. J Gen Intern Med 2000; 15(5)284–92
   PubMed Web of Science ®Google Scholar
• Goldenberg IM, White K, Yonkers K, et al. The infrequency of “pure culture” diagnoses among the anxiety disorders. J Clin Psychiatry 1996; 57(11)528–33
   Google Scholar
• Hirschfield RM. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Primary Care Companion. J Clin Psychiatry 2001; 3(6)244–54
   Google Scholar
• Beekman AT, de Beurs E, van Balkom AJ, et al. Anxiety and depression in later life: Co-occurrence and communality of risk factors. Am J Psychiatry 2000; 157(1)89–95
   PubMed Web of Science ®Google Scholar
• Flint AJ. Generalised anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. Drugs Aging 2005;22(2):101–14 [Review].
   PubMed Web of Science ®Google Scholar
• Vollrath M, Koch R, Angst J. The Zurich Study. IX Panic disorder and sporadic panic: Symptoms, diagnosis, prevalence and, overlap with depression. Eur Arch Psychiatr Neurol Sci 1990; 239: 221–30
   PubMedGoogle Scholar
• Sherbourne CD, Wells KB, Meredith LS, Jackson CA, Camp P. Comorbid anxiety disorder and the functioning and well-being of chronically ill patients of general medical providers. Arch Gen Psychiatry 1996; 53(10)889–95
   PubMed Web of Science ®Google Scholar
• Olfson M, Fireman B, Weissman MM, et al. Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 1997; 154(12)1734–40
   PubMed Web of Science ®Google Scholar
• Kessler RC, Stang PE, Wittchen HU, Ustun TB, Roy-Burne PP, Walters EE. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 1998; 55(9)801–8
   PubMed Web of Science ®Google Scholar
• Kessler RC, DuPont RL, Berglund P, Wittchen H-U. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999; 156: 1915–23
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ, et al. British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19(6)567–96
   PubMed Web of Science ®Google Scholar
• Peveler R, Kendrick T. Treatment delivery and guidelines in primary care. Br Med Bull 2001; 57: 193–206
   PubMed Web of Science ®Google Scholar
• Gilbody S, Whitty P, Grimshaw J, Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. J Am Med Assoc 2003;289(23):3145–51 [Review].
   PubMed Web of Science ®Google Scholar
• Lazarus A. Economic grand rounds: the promise of disease management. Psychiatr Serv 2001; 52: 169–71
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry 2004; 65(Suppl 13)20–6
   Google Scholar
• Neumeyer-Gromen A, Lampert T, Stark K, Kallischnigg G. Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials. Med Care 2004; 42: 1211–21
   PubMedGoogle Scholar
• Guidelines and Protocols Advisory Committee (GPAC). Diagnosis and Management of Major Depressive Disorder. Victoria, BC: Ministry of Health; 2004 [ www.hlth.gov.bc.ca/msp/protoguides/gps/depression.pdf].
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40
   PubMed Web of Science ®Google Scholar
• Adli M, Bauer M, Rush AJ. Algorithms and collaborative-care systems for depression: Are they effective and why? A systematic review. Biol Psychiatry 2006; 59: 1029–38
   PubMed Web of Science ®Google Scholar
• Lam RW, Michalak EE, Swinson RP. Assessment scales in depression, mania and anxiety. Taylor and Francis, London 2005
   Google Scholar
• Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 2006; 7: 429–40
   PubMed Web of Science ®Google Scholar
• Sánchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berlin) 2004;174(2):163–76 [Review].
   PubMed Web of Science ®Google Scholar
• Sánchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006;98:91–5.
   Google Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17(2)65–9
   Google Scholar
• Davidson JRT, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2005; 66(11)1441–6
   Google Scholar
• Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186: 222–6
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66(10)1270–8
   PubMed Web of Science ®Google Scholar
• Kasper S, Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2001;11(4):307–21 [Review].
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005; 10(1)49–56
   PubMed Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396–404 [Review].
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–41
   PubMed Web of Science ®Google Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19(5):305–10 [Erratum in: Int Clin Psychopharmacol 2004;19(6):363].
   PubMed Web of Science ®Google Scholar
• Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003;17(5):343–62 [Review].
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Change CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1190–1196
   PubMed Web of Science ®Google Scholar
• Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. J Am Med Assoc 2000;283(19):2529–36 [Erratum in: J Am Med Assoc 2000;284(19):2450; J Am Med Assoc 2001;284(20):2597].
   PubMed Web of Science ®Google Scholar
• Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005;66(Suppl 8):22–9 [Review].
   PubMedGoogle Scholar
• Pull CB. Self-help internet interventions for mental disorders. Curr Opin Psychiatry 2006; 19: 50–3
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Computerised Cognitive Behaviour Therapy for Depression and Anxiety: Guidance. Technical Appraisal 97. London: NICE; 2006 [ www.nice.org.uk/TA097guidance].
   Google Scholar